Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
36.34
-0.27 (-0.74%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Cogent Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
258
Market Cap
5.85B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.73B |
| Caris Life Sciences | 812.03M |
| Rhythm Pharmaceuticals | 189.76M |
| Centessa Pharmaceuticals | 15.00M |
| CG Oncology | 4.04M |
COGT News
- 7 days ago - Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 11 days ago - Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire
- 27 days ago - Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) - GlobeNewsWire
- 6 weeks ago - Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) - GlobeNewsWire
- 6 weeks ago - Cogent Biosciences Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting - GlobeNewsWire
- 2 months ago - Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting - GlobeNewsWire